MK-2206 is a novel, orally active, potent and selective allosteric Akt inhibitor, that inhibits the activities of all three human Akt (recombinant full length) isoforms, Akt1, 2, and 3 with 50% inhibitory concentration (IC50) values of 8, 12, and 65 nM, respectively and which is in phase II of clinical trials and has been tested on acute myelogenous leukemia [15] and on solid tumors, including malignant glioma, melanoma and squamous cell carcinoma [16, 17]. The gene discussed is AKT1; the disease is squamous cell carcinoma.